No Difference of Adalimumab Pharmacokinetics When Dosed at 40 mg Every Week or 80 mg Every Other Week in IBD Patients in Clinical Remission After Adalimumab Dose Intensification.
Stephane PaulNicolas WillietStéphane NanceyPauline VeyrardGilles BoschettiJean-Marc PhelipBernard FlourieXavier RoblinPublished in: Digestive diseases and sciences (2020)
In IBD patients who achieved a deep clinical remission under ADA 40 mg once a week, the pharmacokinetic of ADA was similar when ADA regimen was changed to 80 mg EOW. Given the patient's preference for the latter regimen, a modification of injection regimen should be systematically proposed.
Keyphrases
- ulcerative colitis
- end stage renal disease
- rheumatoid arthritis
- disease activity
- chronic kidney disease
- ejection fraction
- newly diagnosed
- juvenile idiopathic arthritis
- peritoneal dialysis
- prognostic factors
- randomized controlled trial
- patient reported outcomes
- systemic lupus erythematosus
- hidradenitis suppurativa
- clinical trial